<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843891</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000355</org_study_id>
    <nct_id>NCT04843891</nct_id>
  </id_info>
  <brief_title>Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.</brief_title>
  <official_title>Preliminary Evaluation of [64Cu] Macrin in Healthy Individuals and Subjects With Cardiovascular Disease, Sarcoidosis and Malignancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ralph Weissleder, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of [64Cu] Macrin and its whole-body distribution, metabolism,&#xD;
      pharmacokinetics, and radiation burden in healthy volunteers. To detect [64Cu]-Macrin&#xD;
      accumulation in sites of disease in subjects with cancer, sarcoidosis or myocardial infarct.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Macrophages are phagocytic cells of the innate immune system. Their accumulation is a&#xD;
      hallmark of many inflammatory diseases and they have diverse roles in tissue responses to&#xD;
      infection and injury and in tissue repair. As macrophages have a tissue specific and often&#xD;
      disease stage specific roles, future therapies directed at macrophage subtypes at certain&#xD;
      points in the course of a disease may be more efficacious and result in less systemic side&#xD;
      effects, as compared to conventional chemotherapeutics. [64Cu] Macrin is designed to detect&#xD;
      macrophages by PET imaging. As a result, PET imaging can be used to identify inflammatory&#xD;
      &quot;hotspots&quot; and quantitate local macrophage density non-invasively. The investigators studies&#xD;
      in mice showed that [64Cu] Macrin has excellent pharmacological and pharmacokinetic profile&#xD;
      with high target uptake and low retention in background tissues and organs.&#xD;
&#xD;
      The investigators wish to first evaluate in healthy human subjects the pharmacological and&#xD;
      pharmacokinetic profile, and the overall safety of the new radiopharmaceutical [64Cu] Macrin.&#xD;
      The investigators will then establish the concentration of [64Cu] Macrin in patients&#xD;
      following myocardial infarct, in sarcoidosis and in cancer patients. In a subset of patients&#xD;
      where tissue sampling is feasible, we will correlate tracer uptake on imaging to macrophage&#xD;
      density on histopathology or with additional standard of care imaging studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Eligible subjects, including healthy volunteers and patients with sarcoidosis, cardiovascular disease and cancer, will be enrolled to undergo imaging with the PET Probe [64]Cu Macrin</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish human dosimetry of 64Cu Macrin in Healthy Volunteers</measure>
    <time_frame>1 year</time_frame>
    <description>We will use established methods to provide quantitative information on the amount of [64Cu] Macrin radioactivity that accumulates in peripheral organs and brain. Dose-corrected imaging data will be processed using time-activity curves based on ROIs manually-drawn on MR data and projected onto PET datasets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[64Cu] Macrin accumulation and detection in cancer</measure>
    <time_frame>1 year</time_frame>
    <description>Probe uptake will be measured in organs affected by solid epithelial malignancies and compared to uptake in the uninvolved parts of the organs and in these organs in healthy volunteers. We expect greater uptake in the part of the organs affected by malignancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[64Cu] Macrin accumulation and detection in myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>Probe uptake will be measured at a myocardial infarct and compared to uptake in the remainder of the heart and in the hearts of healthy volunteers. We expect greater uptake at the site of a myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[64Cu] Macrin accumulation and detection in sarcoidosis</measure>
    <time_frame>1 year</time_frame>
    <description>Probe uptake will be measured in the heart and lungs of patients with sarcoidosis and compared to uptake in these organs in healthy volunteers. We expect greater uptake in the organs affected by sarcoidosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[64Cu] Macrin accuracy for macrophage localization</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the sensitivity and specificity of [64 Cu] Macrin accumulation for the detection at sites of inflammation by comparing tracer accumulation to histopathology and/or standard of care imaging studies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sarcoid</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In 10 healthy volunteers the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiovascular Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In 30 subjects with a history of recent myocardial infarct, the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the infarct site will be correlated with cardiac MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In 30 subjects with an epithelial malignancy the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In 30 subjects with sarcoidosis the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[64]Cu Macrin</intervention_name>
    <description>Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.</description>
    <arm_group_label>Cancer</arm_group_label>
    <arm_group_label>Cardiovascular Disease</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Sarcoidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1: Healthy subjects&#xD;
&#xD;
          -  Must be 18 years of age or older&#xD;
&#xD;
          -  Must be deemed healthy at screening visit, as determined by the physician investigator&#xD;
             or nurse practitioner, based on the following assessments at screening: physical&#xD;
             examination, medical history and vital signs;&#xD;
&#xD;
               -  No known history of pre-existing cardiac or respiratory disease or malignancy&#xD;
&#xD;
               -  Have the ability to give written informed consent.&#xD;
&#xD;
        Group 2: Myocardial Infarction&#xD;
&#xD;
          -  History of percutaneous coronary intervention (PCI) for acute or chronic coronary&#xD;
             syndrome (within 3-5 days)&#xD;
&#xD;
          -  Have the ability to give written informed consent&#xD;
&#xD;
          -  Must be 18 years of age or older&#xD;
&#xD;
          -  Hemodynamically stable&#xD;
&#xD;
        Group 3: Sarcoidosis&#xD;
&#xD;
          -  A suspected or confirmed diagnosis of intrathoracic sarcoidosis&#xD;
&#xD;
          -  Have the ability to give written informed consent&#xD;
&#xD;
          -  Must be 18 years of age or older&#xD;
&#xD;
        Group 4: Malignancy&#xD;
&#xD;
          -  Suspected or confirmed thoracic, intra-abdominal or pelvic malignancy&#xD;
&#xD;
          -  Have the ability to give written informed consent&#xD;
&#xD;
          -  Must be 18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Electrical implants, such as cardiac pacemaker or perfusion pump;&#xD;
&#xD;
               -  Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,&#xD;
                  artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic&#xD;
                  tattoos anywhere on the body, tattoos near the eye, or steel implants&#xD;
                  ferromagnetic objects such as jewelry or metal clips in clothing;&#xD;
&#xD;
               -  eGFR of less than 30 mL/min/1.73 m2 within the past 30 days;&#xD;
&#xD;
               -  Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is&#xD;
                  required for females having child-bearing potential before the subject can&#xD;
                  participate);&#xD;
&#xD;
               -  Self-reported or documented claustrophobic reactions;&#xD;
&#xD;
               -  Research-related radiation exposure exceeds current Radiology Department&#xD;
                  guidelines (i.e. 50 mSv in the prior 12 months);&#xD;
&#xD;
               -  Unable to lie comfortably on a bed inside the MR-PET;&#xD;
&#xD;
               -  BMI &gt; 33 (limit of the PET-MRI table);&#xD;
&#xD;
               -  Determined by the investigator(s) to be clinically unsuitable for the study (e.g.&#xD;
                  based on screening visit and/or during study procedures);&#xD;
&#xD;
               -  Stroke within the last 3 months;&#xD;
&#xD;
               -  Cardiac or major surgery within the last 3 months;&#xD;
&#xD;
               -  History of abnormal heart rate including persistent tachyarrhythmia (heart rate&#xD;
                  persistently &gt;120 bpm) or bradyarrhythmia (heart rate persistently &lt; 50 bpm);&#xD;
&#xD;
               -  History of atrial premature complexes with daytime pauses &gt; 3s;&#xD;
&#xD;
               -  Contraindications to gadolinium-based contrast agents, including an eGFR &lt; 30&#xD;
                  mL/min (myocardial infarction and sarcoidosis patients only).&#xD;
&#xD;
               -  History of myeloproliferative disorder.&#xD;
&#xD;
               -  Age &gt;80 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Weissleder, MD, PhD</last_name>
      <phone>617-726-8226</phone>
      <email>RWEISSLEDER@PARTNERS.ORG</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aileen O'Shea</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aileen O'Shea, MD</last_name>
      <phone>857-250-9201</phone>
      <email>aoshea1@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Lewis, MD</last_name>
      <email>ALEWIS33@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ralph Weissleder, MD</investigator_full_name>
    <investigator_title>Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

